



TITLE:

CFHandVIPR2as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy

AUTHOR(S):

Hosoda, Yoshikatsu; Yoshikawa, Munemitsu; Miyake, Masahiro; Tabara, Yasuharu; Ahn, Jeeyun; Woo, Se Joon; Honda, Shigeru; ... Matsuda, Fumihiko; Tsujikawa, Akitaka; Yamashiro, Kenji

CITATION:

Hosoda, Yoshikatsu ...[et al]. CFHandVIPR2as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy. Proceedings of the National Academy of Sciences of the United States of America 2018, 115(24): 6261-6266

ISSUE DATE:

2018-06-12

URL:

<http://hdl.handle.net/2433/231312>

RIGHT:

2018 the Author(s). Published by PNAS. This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

CFH and VIPR2 as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy

Yoshikatsu Hosoda^{a,b}, Munemitsu Yoshikawa^{a,b}, Masahiro Miyake^{a,b}, Yasuharu Tabara^b, Jeeyun Ahn^c, Se Joon Woo^d, Shigeru Honda^e, Yoichi Sakurada^f, Chieko Shiragami^g, Hideo Nakanishi^h, Akio Oishi^a, Sotaro Ooto^a, Akiko Miki^e, Nagahama Study Group¹, Tomohiro Iida^h, Hiroyuki Iijima^f, Makoto Nakamura^e, Chiea Chuen Khor^{i,j}, Tien Yin Wong^{i,k,l}, Kyuyoung Song^m, Kyu Hyung Park^d, Ryo Yamada^b, Fumihiko Matsuda^b, Akitaka Tsujikawa^a, and Kenji Yamashiro^{a,n,2}

^aDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 6068507 Kyoto, Japan; ^bCenter for Genomic Medicine, Kyoto University Graduate School of Medicine, 6068503 Kyoto, Japan; ^cDepartment of Ophthalmology, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, 07061 Seoul, Korea; ^dDepartment of Ophthalmology, Seoul National University Bundang Hospital, College of Medicine Kyeonggi, Seoul National University, 13620 Seoul, Korea; ^eDepartment of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, 6500017 Kobe, Japan; ^fDepartment of Ophthalmology, University of Yamanashi, 4008510 Yamanashi, Japan; ^gDepartment of Ophthalmology, Kagawa University, 7610793 Kagawa, Japan; ^hDepartment of Ophthalmology, Tokyo Womens' Medical University, 1628666 Tokyo, Japan; ⁱSingapore National Eye Centre, Singapore Eye Research Institute, 168751 Singapore; ^jDivision of Human Genetics, Genome Institute of Singapore, 138672 Singapore; ^kSaw Swee Hock School of Public Health, National University of Singapore and National University Health System, 117549 Singapore; ^lOphthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, National University of Singapore, 169857 Singapore; ^mDepartment of Biochemistry and Molecular Biology, University of Ulsan College of Medicine, 138736 Seoul, Korea; and ⁿDepartment of Ophthalmology, Otsu Red-Cross Hospital, 5208511 Otsu, Japan

Edited by Emily Y. Chew, National Eye Institute, NIH, Bethesda, MD, and accepted by Editorial Board Member Jeremy Nathans May 7, 2018 (received for review February 9, 2018)

Central serous chorioretinopathy (CSC) is a common disease affecting younger people and may lead to vision loss. CSC shares phenotypic overlap with age-related macular degeneration (AMD). As recent studies have revealed a characteristic increase of choroidal thickness in CSC, we conducted a genome-wide association study on choroidal thickness in 3,418 individuals followed by TaqMan assays in 2,692 subjects, and we identified two susceptibility loci: *CFH* rs800292, an established AMD susceptibility polymorphism, and *VIPR2* rs3793217 ($P = 2.05 \times 10^{-10}$ and 6.75×10^{-8} , respectively). Case-control studies using patients with CSC confirmed associations between both polymorphisms and CSC ($P = 5.27 \times 10^{-5}$ and 5.14×10^{-5} , respectively). The *CFH* rs800292 G allele is reportedly a risk allele for AMD, whereas the A allele conferred risk for thicker choroid and CSC development. This study not only shows that susceptibility genes for CSC could be discovered using choroidal thickness as a defining variable but also, deepens the understanding of differences between CSC and AMD pathophysiology.

GWAS | choroidal thickness | *CFH* | *VIPR2* | central serous chorioretinopathy

Central serous chorioretinopathy (CSC) constitutes a common eye disease characterized by serous detachment of the central retina (1). The incidence of CSC is reportedly around 10 per 100,000 in men and 2 per 100,000 in women (2). CSC can spontaneously resolve, but 30–50% of cases become chronic and/or recurrent, which results in severe retinal tissue damage and permanent vision loss (3–5). Recent studies suggest that eyes with CSC may be at higher risk of developing age-related macular degeneration (AMD) or its subtype of polypoidal choroidal vasculopathy (PCV) even after spontaneous resolution of CSC or that the development of CSC and AMD/PCV may share a common background (6, 7).

Although the precise pathogenesis of CSC has not yet been elucidated, genetic factors may contribute to CSC occurrence. Familial clustering of CSC has been reported (8–10), and the prevalence of CSC varies in different populations, being high in Caucasians and Hispanics, with the highest prevalence reported in Asians and an extremely low prevalence found in African Americans; these differences may also reflect genetic predisposition (11). To date, genome-wide association studies (GWASs) have not reported any susceptibility genes for CSC. However, three candidate gene studies have evaluated the established

AMD susceptibility gene *CFH* as a putative gene in CSC (12–14). Notably, all reported that the *CFH* risk alleles associated with AMD appeared as protective alleles for CSC, although these two diseases might share pathophysiological overlap. There is no clear explanation of why these alleles in *CFH* confer opposite effects in the development of AMD and CSC. Other than *CFH*, no other susceptibility gene for CSC has been identified, although some candidate gene studies reported possible genes of interest (15–17).

Significance

Although central serous chorioretinopathy (CSC) presumptively shares pathophysiological basis with age-related macular degeneration (AMD), the *CFH* risk alleles for AMD are reportedly protective against CSC development. Our finding, that the *CFH* risk allele for AMD is protective against choroidal thickening in a Japanese cohort, indicates that *CFH* affects CSC development through its choroid-thickening effects rather than its association with AMD, highlighting the need for a new AMD classification, with CSC/pachychoroid-associated choroidal neovascularization as a distinct disease. Furthermore, our genome-wide association study (GWAS) addressing choroidal thickness successfully discovered a susceptibility gene for CSC: *VIPR2*. Future GWASs on choroidal thickness will likely discover additional CSC susceptibility genes and provide key molecules to elucidate the pathophysiological difference between CSC and AMD.

Author contributions: Y.T., S.J.W., N.S.G., T.I., H.I., M.N., T.Y.W., K.S., R.Y., F.M., and K.Y. designed research; Y.H., M.Y., M.M., Y.T., J.A., S.H., Y.S., C.S., H.N., A.O., S.O., A.M., C.C.K., K.H.P., A.T., and K.Y. performed research; Y.H., M.Y., M.M., J.A., S.H., Y.S., C.S., H.N., A.O., S.O., A.M., C.C.K., K.H.P., A.T., and K.Y. analyzed data; and Y.H., M.M., and K.Y. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission. E.Y.C. is a guest editor invited by the Editorial Board.

This open access article is distributed under [Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 \(CC BY-NC-ND\)](#).

¹A complete list of the Nagahama Study Group can be found in *SI Appendix*.

²To whom correspondence should be addressed. Email: yamashiro@kuhp.kyoto-u.ac.jp.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1802212115/-DCSupplemental.

Recent progress in imaging technology for use in the diagnosis and monitoring of eye diseases has revealed that the choroid, from where fluid leaks into the subretinal space to cause retinal detachment in CSC, is thicker in eyes with CSC than in normal eyes (18). This finding is in accordance with a previous suggestion of choroidal vessel hyperpermeability in the pathogenesis of CSC and that increased choroidal thickness is considered the start of CSC development. Increased choroidal thickness is also reported to be inherited (19). In this study, we performed GWAS on choroidal thickness in a Japanese community-based cohort to discover putative candidate genes, and using case-control studies, we further evaluated whether there was an association between these discovered genes and CSC development. We found robust evidence of association of two susceptibility loci, rs800292 in *CFH* and rs3793217 in *VIPR2*, with choroidal thickness and CSC development.

Results

Two-Stage GWAS for Choroidal Thickness. To investigate and identify genetic loci associated with choroidal thickness, subfoveal choroidal thickness in the right eye was used as the dependent variable for genome-wide quantitative trait loci (QTL) analyses in 6,110 participants from the Nagahama Prospective Cohort for Comprehensive Human Bioscience (the Nagahama Study) (SI Appendix, Table S1). We included age, sex, axial length, and the first principal component as covariates. A genomic inflation factor lambda of 0.9991 indicated excellent control of the study population substructure (SI Appendix, Fig. S1).

For this two-stage GWAS, experiment-wide significance was set at 5.0×10^{-8} ; additionally, we also tested SNPs with P values less than 5.0×10^{-7} in the replication stage as findings indicative of association. During the discovery stage using 4,710,779 SNPs from 3,418 participants, we identified genome-wide significant association near the *CFH* locus with rs3753394 ($P = 2.44 \times 10^{-8}$) (Fig. 1 and Table 1) and indicative evidence of association at *VIPR2* with rs7782658 ($P = 4.03 \times 10^{-7}$). The respective SNP association plots for the *CFH* and *VIPR2* regions are shown in Figs. 2 and 3, respectively. *CFH* rs3753394 was in moderate linkage disequilibrium with rs800292, which is a widely known susceptibility SNP for AMD ($R^2 = 0.721$ in the discovery set). Because rs800292 also showed strong association with choroidal thickness ($P = 8.43 \times 10^{-8}$) in the discovery stage, we chose rs800292 as a candidate SNP to be analyzed in the replication stage.

Conversely, for another putative susceptibility SNP, rs7782658 at the *VIPR2* locus, a commercially designed TaqMan probe was not available. Thus, to facilitate replication studies by other

groups, we sought SNPs in commercially available microarrays. Among the *VIPR2* SNPs found in both Illumina and Affymetrix microarrays, rs3793217 had the strongest association with choroidal thickness ($P = 1.28 \times 10^{-6}$) (Fig. 3). Because rs3793217 was in moderate linkage disequilibrium with rs7782658 ($R^2 = 0.605$ in the discovery set), we analyzed rs3793217 in the replication stage (Fig. 3).

In the replication stage with 2,692 participants, both *CFH* rs800292 and *VIPR2* rs3793217 showed significant association with choroidal thickness ($P = 4.37 \times 10^{-4}$ and $P = 7.58 \times 10^{-3}$, respectively). Meta-analysis of the discovery and replication sets further confirmed robust association of *CFH* rs800292 and *VIPR2* rs3793217 with choroidal thickness ($P = 2.05 \times 10^{-10}$ and $P = 6.75 \times 10^{-8}$, respectively).

Association of *CFH* and *VIPR2* with CSC. Next, the two SNPs identified during the GWAS for choroidal thickness, rs800292 in *CFH* and rs3793217 in *VIPR2*, were evaluated to determine whether they were associated with CSC in a Japanese case-control study. We collected 701 DNA samples of patients with CSC from five facilities in Japan, among which most of the samples from Kobe University Hospital had already been tested for an association between rs800292 and CSC (12). Thus, we used 539 CSC cases from the four remaining facilities for the case-control study of rs800292 by comparing its genotype distribution with that of the entire Nagahama cohort as a control group. The genotype distribution of rs800292 did not significantly deviate from Hardy-Weinberg equilibrium (HWE) in either our cohort of patients with CSC or Nagahama controls (both $P > 0.05$). In our test cohort, *CFH* rs800292 was associated with CSC development ($P = 5.27 \times 10^{-5}$) (Table 2).

To test for association between *VIPR2* and CSC, we used all 701 CSC DNA samples. We found that rs3793217 was in HWE in both our CSC cohort and the Nagahama control cohort ($P > 0.05$) and that rs3793217 also showed significant association with CSC development in the Japanese ($P = 4.59 \times 10^{-4}$) (Table 3).

Although the association between *CFH* and CSC has been evaluated in other ethnicities (13, 14), an association between *VIPR2* and CSC had not been investigated. Therefore, we conducted further replication analyses to test for evidence of an association between rs3793217 and CSC in a Korean population. In a case-control study using 425 patients with CSC and 1,643 controls, we found that rs3793217 showed significant association, with an odds ratio similar to that found in the Japanese analysis ($P = 0.038$). In addition, a meta-analysis using data from both




Fig. 1. Manhattan plots of the discovery-stage GWAS for subfoveal choroidal thickness. Each plot shows $-\log_{10}(\text{transformed } P \text{ values})$ for all SNPs. The upper horizontal line represents the genome-wide significance threshold of 5.0×10^{-8} , and the lower horizontal line represents the indicative threshold of 5.0×10^{-7} .

Table 1. Discovery stage to identify SNPs associated with choroidal thickness

SNP	CHR	Position	Effect allele	EAF	Nearby genes	Discovery stage			Replication stage			Meta-analysis		
						N	β	P	N	β	P	N	β	P
rs3753394	1	196620917	C	0.487	<i>CFH</i> (nearby)	3,418	11.84	2.44×10^{-8}	—	—	—	—	—	—
rs800292	1	196642233	A	0.406	<i>CFH</i> (in gene)	3,418	11.55	8.43×10^{-8}	2,692	8.61	4.37×10^{-4}	6,110	10.27	2.05×10^{-10}
rs7782658	7	158858007	A	0.307	<i>VIPR2</i> (in gene)	3,418	11.59	4.03×10^{-7}	—	—	—	—	—	—
rs3793217	7	158848821	G	0.213	<i>VIPR2</i> (in gene)	3,418	12.46	1.28×10^{-6}	2,692	7.69	7.58×10^{-3}	6,110	10.34	6.75×10^{-8}

CHR, chromosome; EAF, effect allele frequency in the discovery stage.

ethnicity groups revealed additional support for an association between *VIPR2* rs3793217 and CSC ($P = 5.14 \times 10^{-5}$).

Association Between *CFH* and *VIPR2* with Axial Length. Because choroidal thickness becomes thinner in eyeballs with a longer axial length (20), we next evaluated whether there was an association between rs800292 and rs3793217 with axial length in the right eye using the entire Nagahama cohort. In our cohort of 6,110 participants, we found no association between either rs800292 or rs3793217 with axial length ($P = 0.074$ and $P = 0.30$, respectively) on linear regression analysis.

Association of Previously Reported Putative CSC Susceptibility Genes with Choroidal Thickness and CSC in a Japanese Population. Of the SNPs analyzed in the discovery stage, no SNPs in the *C4B* region were associated with choroidal thickness ($P > 0.05$), although significant associations between *C4B* genomic copy numbers and CSC were previously reported (16). Within the regions of *NR3C2* and *CDH5*, which are two previously reported putative susceptibility genes for CSC (15, 17), rs10519952 in *NR3C2* ($P = 0.030$) showed nominally significant association with choroidal thickness in our GWAS discovery stage (SI Appendix, Figs. S2 and S3 and Table S2). However, no association was found for the SNP with CSC development in our case-control study using 250 Japanese CSC samples genotyped with the HumanExome chip and genome-wide genotyping data of 3,418 controls from the Nagahama cohort (SI Appendix, Table S3).

Discussion

Our GWAS using a Japanese cohort identified two genes significantly associated with choroidal thickness, *CFH* and *VIPR2*; moreover, these genes were also significantly associated with the occurrence of CSC in a Japanese case-control study. Although *CFH* constitutes an established susceptibility gene for AMD and three previous studies also reported an association between *CFH* and CSC (12–14), no prior GWAS has investigated *CFH* in relation to choroidal thickness. Furthermore, the conflicting report that the *CFH* risk alleles for AMD were protective for CSC, two diseases with a possible shared pathophysiological basis, has not been clearly explained. Our GWAS discovery of a significant association between *CFH* and choroidal thickness suggested that *CFH* affects the occurrence of CSC via its effects on choroidal thickness rather than via the previously suspected pathophysiological overlap between CSC and AMD. In turn, our findings regarding *VIPR2* were supported by the replication of its association with CSC in a Korean cohort. Considering that the minor allele frequency of *VIPR2* rs3793217 is low in many ethnicities, haplotype-tagged SNP analysis may be needed for further replication studies in other populations, which is warranted to determine whether *VIPR2* represents a common susceptibility gene for CSC or is specific to Asian populations.

Using choroidal thickness in GWAS to discover susceptibility genes for CSC is demonstrably warranted, because hyperpermeability of choroidal vessels has been considered a strong candidate as the main cause of CSC for over 50 y (21). Choroidal hyperpermeability is predicted to result in a thicker choroid;

accordingly, recent progress in eye imaging technology has enabled us to confirm a thick choroid in the eyes of most patients with CSC (18). Although some patients with CSC have a thinner choroid than normal and not all eyes with a thicker choroid will develop CSC, the discovery of two potential susceptibility genes for CSC via GWAS for choroidal thickness supports the premise that a thick choroid makes up at least one of the major contributing factors in the development of CSC. Because recent population-based cohort studies often included optical coherence tomography (OCT) examination as part of their assessment, meta-analysis of GWASs for choroidal thickness measured by OCT may discover additional susceptibility genes for CSC. The fact that not all eyes with a thicker choroid develop CSC likely indicates that CSC develops via a multistep process. The first step is increased choroidal thickness, which may confer greater susceptibility to CSC, with a second step that may include a trigger to cause CSC in those eyes with a thick choroid. Further studies using CSC cohorts subgrouped by genes associated with choroidal thickness may identify the genes associated with the next step of CSC development as representing the trigger causing CSC in eyes with a thicker choroid. Furthermore, as choroidal structure is complex, GWASs for choroidal vessel thickening/dilation, choroidal hyperpermeability, choroidal vascularity index, and choroidal thickness change in each individual might be able to specify more genes associated with choroidal thickness and CSC.

The discovery of genes associated with choroidal thickness and CSC occurrence signifies that treatment strategies for CSC may be developed by focusing on the mechanisms that underlie thicker choroid. It is well-known that *CFH* is expressed in choroidal vessels (22) and that *VIPR2* is expressed in the retina and choroid (23, 24). Pathways including *CFH* or *VIPR2* may serve as promising targets to treat CSC by controlling choroidal thickness.




Fig. 2. Regional association plots for genotyped SNPs in *CFH* regions. Plots represent the $-\log_{10}(P \text{ values})$ obtained from the first-stage GWAS. Each P value was calculated by age-, sex-, axial length-, and first principal component-adjusted QTL analysis.




Fig. 3. Regional association plots for genotyped SNPs in *VIPR2* regions. Plots represent the $-\log_{10}(P \text{ values})$ obtained from the first-stage GWAS. Each P value was calculated by age-, sex-, axial length-, and first principal component-adjusted QTL analysis.

In addition, *VIPR2* expression is up-regulated by *Helicobacter pylori* infection, a known risk factor of CSC development (25, 26). Notably, the *VIPR2* agonist vasoactive intestinal peptide can control corticosteroid secretion in addition to its vasodilatory effects in various vascular tissues (27–29). Further studies on *CFH* and *VIPR2* pathways are warranted to identify new treatments for CSC.

An important factor in the interpretation of associations between *CFH* and *VIPR2* with choroidal thickness and CSC is the size of the eyeball as determined by axial length. A longer axial length results in myopia (nearsightedness). Because choroidal thickness is thinner in myopic eyeballs with a longer axial length (20), we included axial length as an adjustment factor in our GWAS on choroidal thickness. In fact, in addition to its association with choroidal thickness and CSC occurrence, rs800292 showed indicative, but not significant, association with axial length in our Japanese cohort ($P = 0.073$). Although *VIPR2* did not show significant association with axial length, two previous studies in Chinese populations showed a significant association between *VIPR2* and axial length/myopia by evaluating other SNPs in *VIPR2* (23, 30). However, there were no previous reports regarding the association of *CFH* with axial length/myopia, and *VIPR2* was not included as 1 of 51 major myopia-related genes reported in large-scale GWASs for myopia using more than 45,000 samples (31, 32), an omission that suggests that *CFH* and *VIPR2* have minor roles in myopia development. Both *CFH* and *VIPR2* may thus directly influence CSC occurrence by affecting choroidal thickness rather than through their effect on axial length.

In this study, we generated robust evidence that *CFH* constitutes a susceptibility gene for CSC. Notably, *CFH* is also an established susceptibility gene for AMD (22). Our previous study showed that the G allele of rs800292 in *CFH* was a risk allele for AMD with an odds ratio of 2.12 in the Japanese (33). In comparison, the rs800292 A allele was a risk allele for CSC with an

odds ratio of 1.30 in this study, with previous studies also reporting the A allele as a risk allele for CSC with odds ratios of 1.66 and 1.50 in Japanese (12) and Caucasians (13), respectively. We posit that the recent findings of choroidal thickness being thinner in AMD and thicker in CSC (34) can be accounted for by the effects of the rs800292 G allele toward reducing choroidal thickness in AMD and the A allele toward promoting thicker choroid in CSC.

The possibility of a pathophysiological overlap between CSC and AMD has facilitated analyses toward identifying associations between CSC and AMD (6) or between CSC and AMD susceptibility genes (13). However, an overlap between the pathophysiology of these diseases cannot explain the opposing effects conferred by the same genetic polymorphisms in the respective development of CSC and AMD. Recently, another theory was proposed that a thick choroid, termed pachychoroid from the ancient Greek, serves as a common background of CSC and an AMD-like disorder that should be distinguished from AMD named pachychoroid neovascularopathy (PCN) (35). Thus, the seemingly contrasting findings between *CFH* and AMD vs. *CFH* and CSC/thick choroid in our study would support the need to distinguish pachychoroid and PCN from AMD in clinical settings, with the premise that PCN and AMD have different underlying pathophysiologies. Currently, a clear definition to differentiate PCN from AMD has not yet been established, because PCN shares many clinical characteristics with AMD. Further genetic studies using choroidal thickness, CSC, PCN, and AMD may reveal the detailed underlying relationships of these three diseases and enable tailored treatment strategies in the future.

Candidate gene studies previously reported that SNPs in *CDH5* and *NR3C2* and gene copy number variations in *C4B*, but not SNPs, were significantly associated with CSC development (15–17). In our GWAS discovery cohort, we found that no SNPs or indels in *C4B* and *CDH5* showed significant association with choroidal thickness. Although an SNP in *NR3C2* ($P = 0.030$) showed nominally significant associations with choroidal thickness, it was not significantly associated with CSC development. Furthermore, because the allele effects were opposite from those found in the original report, we concluded that *CDH5* and *NR3C2* do not make up susceptibility genes for CSC in our Japanese population.

In conclusion, using GWAS, we identified significant associations between *CFH* and *VIPR2* with choroidal thickness and robustly showed significant associations of *CFH* and *VIPR2* with the development of CSC. Based on our findings, we propose that *CFH* and *VIPR2* contribute to the pathogenesis of CSC via their effects on choroidal thickness. Our findings also indicate that the difference in choroidal thickness found between CSC and AMD, where CSC has a thicker choroid and AMD has a thinner choroid, may be accounted for by genetic differences between the two diseases. Our genetic study thus provides the basis for understanding the roles of choroidal thickness in CSC and AMD.

Methods

Study Participants for the Choroidal Thickness GWAS. The study population consisted of healthy Japanese volunteers enrolled in the Nagahama Study. Participants were recruited between 2008 and 2010 from the general population of Nagahama in Japan (36, 37). Community residents living independently

Table 2. Association between *CFH* rs800292 and CSC in the Japanese

Ethnicity	Major/minor allele	Control		CSC		Odds ratio (95% CI)	P^*
		<i>N</i>	MAF	<i>N</i>	MAF		
Japanese	G/A	6,110	0.401	539	0.464	1.29 (1.14–1.47)	5.27×10^{-5}

MAF, minor allele frequency.

* P values derived using χ^2 test.

Table 3. Association between *VIPR2* rs3793217 and CSC

Ethnicity	Major/minor allele	Control		CSC		Odds ratio (95% CI)	P*
		N	MAF	N	MAF		
Japanese	A/G	6,110	0.213	701	0.254	1.26 (1.11–1.43)	4.59×10^{-4}
Korean	A/G	1,643	0.201	425	0.234	1.21 (1.01–1.45)	0.038
Meta	—	7,753	—	1,126	—	1.24 (1.12–1.38)	5.14×10^{-5}

MAF, minor allele frequency.
*P values derived using χ^2 test.

and without physical impairment or dysfunction were eligible. Blood sampling was performed at the time of enrollment. Of the 9,804 recruited participants, 14 withdrew consent to participate, and 26 were excluded, because genetic analysis indicated an ethnic background other than Japanese. Participants were offered physical and ophthalmic evaluation 5 y after the baseline evaluation from 2013 to 2015, and 8,289 of the original 9,764 cohort members, ages between 34 and 80 y old, participated.

In the follow-up assessment, all subjects underwent ophthalmic examinations, including an objective determination of the refractive error and corneal curvature using an Autorefractor ARK-530 (Nidek), axial length measurements by partial coherence interferometry with an IOL Master (Carl Zeiss Meditec, Inc.), color fundus imaging using a CD-DG10 (Canon), and a cross-line scan of spectral domain OCT examination using an RS-3000 Advance (Nidek) with an enhanced depth imaging (EDI) technique.

In this study, we used a dataset of the follow-up measurements. Study subjects consisted of individuals with available DNA samples as well as age, sex, axial length, fundus imaging, and OCT data. Exclusion criteria included prior intraocular surgery (except for cataract surgery), laser photocoagulation, and the presence of other macular-involving diseases that may affect choroidal thickness, such as active CSC, neovascular AMD, dry AMD with geographic atrophy, retinal vein occlusion, retinoschisis, macular hole, focal choroidal excavation, drusen, retinal pigment epithelium (RPE) damage, pigment epithelium detachment, or macular edema. Subjects with poor-quality images of fundus OCT were excluded. Highly myopic samples with axial length longer than 26 mm were also excluded from analysis.

The Kyoto University Graduate School and Faculty of Medicine Ethics Committee and the Nagahama Municipal Review Board of Personal Information Protection approved the study protocol and procedures used to obtain informed consent. All study procedures adhered to the tenets of the Declaration of Helsinki. All participants were fully informed regarding the purpose and procedures of the study, and written consent was obtained from each subject. Patient records and information were anonymized before analysis.

Evaluation of Choroidal Thickness. Images of the foveal line EDI OCT scans centered on the fovea in right eyes were used to measure choroidal thickness. The choroidal-scleral interface was defined manually as the hyperreflective line behind the large choroidal vessel layers, and choroidal thickness was automatically measured between the RPE line and the choroidal-scleral interface at 1,024 points along the horizontal and vertical scans. The average thickness of points 512 and 513 on both scans was defined as the subfoveal choroidal thickness.

Genome-Wide SNP Genotyping and Statistical Analysis. Genome-wide QTL analysis was performed using subfoveal choroidal thickness in the discovery set of the Nagahama cohort. For every SNP that passed quality control, we evaluated whether there was an association between genotype and subfoveal choroidal thickness using a multivariable linear regression, assuming an additive model. This regression framework allowed us to adjust for covariates, such as age, sex, axial length, and the first principal component. Genome-wide SNP genotyping was performed on samples from 5,324 participants who joined the Nagahama cohort from 2008 to 2009. A series of BeadChip DNA arrays (Illumina), namely HumanHap610 Quad (1,833 samples), HumanOmni2.5-4 (1,611 samples), HumanOmni2.5-8 (375 samples), HumanOmni2.5s (670 samples), CoreExome24 (1,727 samples), and HumanExome (670 samples), were used for the analysis. SNPs with a call rate <99%, a minor allele frequency <1%, or significant deviation ($P < 1.0 \times 10^{-6}$) from HWE were excluded from further statistical analysis. Samples with a call rate <95% were also excluded from the analysis. Subjects estimated to have a first or second degree kinship within this population (π -hat > 0.35) were removed. Samples with genetic analysis that showed an ethnic background other than Japanese were also excluded. Among the remaining subjects, 4,192 individuals were followed 5 y after the baseline evaluation from

2013 to 2015 (*SI Appendix, Fig. S4*). Genotype imputation was performed using MACH (www.sph.umich.edu/csg/abecasis/MACH/tour/imputation.html) with the 1000 Genomes phase 3 v5 release dataset as a reference panel. Imputed SNPs with $R^2 < 0.5$ were excluded from the association analysis. Finally, 4,710,779 SNPs from 3,418 individuals were used for the discovery-stage analysis; 83 samples without sufficient quality EDI OCT images, 54 samples with macular-involving diseases, 49 samples lacking the data of axial length, 237 samples with intraocular surgery or laser photocoagulation, and 351 samples with axial length >26 mm were excluded.

Experiment-wide significance was set at 5.0×10^{-8} . We also tested SNPs with P values less than 5.0×10^{-7} in the replication stage as findings of indicative association. Statistical analyses were performed with R version 3.2.5 (R Foundation for Statistical Computing; available at <https://www.R-project.org/>) and PLINK version 1.9 (<https://www.cog-genomics.org/plink2>).

Replication Genotyping for the Association Study on Choroidal Thickness. In the replication stage using the remaining samples from the Nagahama cohort, rs800292 and rs3793217 were genotyped using TaqMan allelic discrimination probes (Applied Biosystems) with an ABI PRISM 7700 system (Applied Biosystems). Deviations in genotype distributions from HWE were assessed with the χ^2 test. To determine whether there was an association between rs800292 and rs3793217 with choroidal thickness, the subfoveal choroidal thickness in the right eye was used as the dependent variable for multivariable linear regression analysis, including age, sex, and axial length as covariates.

To replicate our findings from the GWAS of choroidal thickness, we used 2,692 samples from the remaining 3,314 individuals of the Nagahama Study; two samples with withdrawn consent, 94 samples without sufficient quality EDI OCT images, 44 samples with macular-involving diseases, 83 samples lacking the data of axial length, 135 samples with intraocular surgery or laser photocoagulation, and 264 samples with axial length >26 mm were excluded. A P value <0.05 was considered statistically significant.

Diagnosis of Patients with CSC. We recruited 701 unrelated Japanese patients with acute, chronic, or steroid-induced CSC from the Kyoto University Hospital, the Kobe University Hospital, the Yamanashi University Hospital, the Fukushima Medical University Hospital, and the Kagawa University Hospital. All procedures adhered to the tenets of the Declaration of Helsinki. The institutional review boards and the ethics committees of the participating institutions approved the study protocols. All patients were fully informed of the purpose and procedures of the study, and written consent was received from each patient before their participation in the study.

All of the patients underwent a comprehensive ophthalmic examination, including dilated funduscopy, color fundus photography, OCT examination including EDI, fundus autofluorescence (FAF), fluorescein angiography (FA), and indocyanine green angiography (ICGA). CSC was diagnosed as an eye with subretinal fluid at the macular region on OCT together with a leakage on FA and choroidal vascular hyperpermeability on ICGA. Eyes with AMD or PCV were excluded. Eyes with RPE damage or atrophic dependent tracks on FA or FAF and choroidal vascular hyperpermeability on ICGA were included as eyes with “inactive CSC,” despite an absence of documented subretinal fluid (38–41).

Association with CSC Development. We genotyped 250 of the 701 CSC samples using the HumanExome chip, and the genotypes of rs800292, rs3793217, and rs7499886 were directly determined from the chip. The genotypes of rs3837775, rs10519952, and rs2075951 were determined by imputation using the Michigan imputation server (<https://imputationserver.sph.umich.edu/index.html>) with the 1000 Genomes phase 3 v5 release dataset as a reference panel (42, 43). For the remaining 451 CSC samples, rs800292 and/or rs3793217 were genotyped using the TaqMan SNP assay. In the case-control study, the discovery and replication sets of the Nagahama cohort were used as control subjects. Deviations in genotype distributions from HWE were

assessed in the CSC cohort with the χ^2 test. The χ^2 test for trend or its exact counterpart was used to compare the genotype distributions between two groups. A P value ≤ 0.05 was considered statistically significant.

Replication Study for Association of VIPR2 rs3793217 with CSC in Koreans. We recruited 425 unrelated Korean patients with acute or chronic CSC at the Seoul National University Bundang Hospital (SNUBH) retina clinic. Control samples consisted of subjects recruited from visitors to the SNUBH healthcare center for regular medical checkups or from patients undergoing cataract surgery at the SNUBH retina clinic ($n = 310$). Control subjects were also participants of the Korean Longitudinal Study on Health and Aging (KLoSHA; $n = 233$) (44) and were from the Korean Reference Genome database ($n = 1,100$; available at [152.99.75.168/KRGDB](https://doi.org/10.1093/bioinformatics/btu111)). All procedures adhered to the tenets of the Declaration of Helsinki. The institutional review boards and the ethics committees of the institutions approved the study protocols. All participants were fully informed of the purpose and procedures of the study,

and written consent was received from each participant. Patients with CSC were genotyped using the TaqMan SNP assay (Applied Biosystems), and controls from the SNUBH and the KLoSHA were genotyped with the OmniExpress array (Illumina). The genotypes of rs3793217 were directly determined from the chip.

ACKNOWLEDGMENTS. We thank Ms. Hatsue Hamanaka for her assistance in genotyping. We also thank the Nagahama City Office and the nonprofit organization Zeroji Club for help in conducting the Nagahama Study. This study was supported by a University Grant from Kyoto University; a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science & Technology in Japan; the Center of Innovation Program and the Global University Project from Japan Science and Technology Agency; the Practical Research Project for Rare/Intractable Diseases and the Comprehensive Research on Aging and Health Science Research Grants for Dementia R&D from Japan Agency for Medical Research and Development; and a research grant from the Takeda Science Foundation.

- Gemenetz M, De Salvo G, Lotery AJ (2010) Central serous chorioretinopathy: An update on pathogenesis and treatment. *Eye (Lond)* 24:1743–1756.
- Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. *Ophthalmology* 115:169–173.
- Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: Update on pathophysiology and treatment. *Surv Ophthalmol* 58:103–126.
- Bujarborua D (2001) Long-term follow-up of idiopathic central serous chorioretinopathy without laser. *Acta Ophthalmol Scand* 79:417–421.
- Bouzas EA, Karadimas P, Pournaras CJ (2002) Central serous chorioretinopathy and glucocorticoids. *Surv Ophthalmol* 47:431–448.
- Ueta T, et al. (2009) Background comparison of typical age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. *Ophthalmology* 116:2400–2406.
- Toyama T, Ohtomo K, Noda Y, Ueta T (2014) Polypoidal choroidal vasculopathy and history of central serous chorioretinopathy. *Eye (Lond)* 28:992–997.
- Oosterhuis JA (1996) Familial central serous retinopathy. *Graefes Arch Clin Exp Ophthalmol* 234:337–341.
- Park DW, et al. (1998) Central serous chorioretinopathy in two families. *Eur J Ophthalmol* 8:42–47.
- Weenink AC, Borsje RA, Oosterhuis JA (2001) Familial chronic central serous chorioretinopathy. *Ophthalmologica* 215:183–187.
- Wang M, Munch IC, Hasler PW, Prunte C, Larsen M (2008) Central serous chorioretinopathy. *Acta Ophthalmol* 86:126–145.
- Miki A, et al. (2014) Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. *Ophthalmology* 121:1067–1072.
- de Jong EK, et al. (2015) Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. *Ophthalmology* 122:562–570.
- Moschos MM, et al. (2016) Prevalence of the complement factor H and *GSTM1* genes polymorphisms in patients with central serous chorioretinopathy. *Retina* 36:402–407.
- Schubert C, et al. (2014) Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. *Hum Mutat* 35:859–867.
- Breukink MB, et al. (2015) Genomic copy number variations of the complement component C4B gene are associated with chronic central serous chorioretinopathy. *Invest Ophthalmol Vis Sci* 56:5608–5613.
- van Dijk EHC, et al. (2017) Association of a haplotype in the NR3C2 gene, encoding the mineralocorticoid receptor, with chronic central serous chorioretinopathy. *JAMA Ophthalmol* 135:446–451.
- Imamura Y, Fujiwara T, Margolis R, Spaide RF (2009) Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. *Retina* 29:1469–1473.
- Lehmann M, Bousquet E, Beydoun T, Behar-Cohen F (2015) PACHYCHOROID: An inherited condition? *Retina* 35:10–16.
- Wei WB, et al. (2013) Subfoveal choroidal thickness: The Beijing eye study. *Ophthalmology* 120:175–180.
- Gass JD (1967) Pathogenesis of disciform detachment of the neuroepithelium. *Am J Ophthalmol* 63(Suppl):1–139.
- Klein RJ, et al. (2005) Complement factor H polymorphism in age-related macular degeneration. *Science* 308:385–389.
- Shi Y, et al. (2013) A genome-wide meta-analysis identifies two novel loci associated with high myopia in the Han Chinese population. *Hum Mol Genet* 22:2325–2333.
- Liu SZ, et al. (2005) Dynamic expression of VIPR2 in form deprivation myopia. *Zhong Nan Da Xue Bao Yi Xue Ban* 30:456–459.
- Rahbani-Nobar MB, Javadzadeh A, Ghojzadeh L, Rafeey M, Ghorbanihaghjo A (2011) The effect of *Helicobacter pylori* treatment on remission of idiopathic central serous chorioretinopathy. *Mol Vis* 17:99–103.
- Cotticelli L, et al. (2006) Central serous chorioretinopathy and *Helicobacter pylori*. *Eur J Ophthalmol* 16:274–278.
- Nowak K, Neri G, Nussdorfer GG, Malendowicz LK (1999) Comparison of the effects of VIP and PACAP on steroid secretion of dispersed rat adrenocortical cells. *Biomed Res* 20:127–132.
- Nussdorfer GG, Malendowicz LK (1998) Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis. *Peptides* 19:1443–1467.
- Henning RJ, Sawmiller DR (2001) Vasoactive intestinal peptide: Cardiovascular effects. *Cardiovasc Res* 49:27–37.
- Yiu WC, Yap MK, Fung WY, Ng PW, Yip SP (2013) Genetic susceptibility to refractive error: Association of vasoactive intestinal peptide receptor 2 (VIPR2) with high myopia in Chinese. *PLoS One* 8:e61805.
- Kiefer AK, et al. (2013) Genome-wide analysis points to roles for extracellular matrix remodeling, the visual cycle, and neuronal development in myopia. *PLoS Genet* 9:e1003299.
- Verhoeven VJ, et al.; Consortium for Refractive Error and Myopia (CREAM); Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group; Wellcome Trust Case Control Consortium 2 (WTCCC2); Fuchs' Genetics Multi-Center Study Group (2013) Genome-wide meta-analyses of multi-ancestry cohorts identify multiple new susceptibility loci for refractive error and myopia. *Nat Genet* 45:314–318.
- Hayashi H, et al. (2010) CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation. *Invest Ophthalmol Vis Sci* 51:5914–5919.
- Kim SW, Oh J, Kwon SS, Yoo J, Huh K (2011) Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy. *Retina* 31:1904–1911.
- Pang CE, Freund KB (2015) Pachychoroid neovascularization. *Retina* 35:1–9.
- Nakata I, et al.; Nagahama Study Group (2015) Calcium, ARMS2 genotype, and Chlamydia pneumoniae infection in early age-related macular degeneration: A multivariate analysis from the Nagahama study. *Sci Rep* 5:9345.
- Miyake M, et al.; Nagahama Study Group (2015) Identification of myopia-associated WNT7B polymorphisms provides insights into the mechanism underlying the development of myopia. *Nat Commun* 6:6689.
- Bernasconi P, Messmer E, Bernasconi A, Thölen A (1998) Assessment of the sympathovagal interaction in central serous chorioretinopathy measured by power spectral analysis of heart rate variability. *Graefes Arch Clin Exp Ophthalmol* 236:571–576.
- Tittl M, et al. (2005) Choroidal hemodynamic changes during isometric exercise in patients with inactive central serous chorioretinopathy. *Invest Ophthalmol Vis Sci* 46:4717–4721.
- Daruich A, et al. (2015) Central serous chorioretinopathy: Recent findings and new pathophysiology hypothesis. *Prog Retin Eye Res* 48:82–118.
- van Velthoven ME, et al. (2005) Evaluation of central serous retinopathy with en face optical coherence tomography. *Br J Ophthalmol* 89:1483–1488.
- Das S, et al. (2016) Next-generation genotype imputation service and methods. *Nat Genet* 48:1284–1287.
- Loh PR, et al. (2016) Reference-based phasing using the haplotype reference consortium panel. *Nat Genet* 48:1443–1448.
- Jhoo JH, et al. (2008) Prevalence of dementia and its subtypes in an elderly urban Korean population: Results from the Korean Longitudinal Study on Health and Aging (KLoSHA). *Dement Geriatr Cogn Disord* 26:270–276.